Healthcare [ 4/11 ] | Biotechnology [ 53/112 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 10, 23 | -0.15 Increased by +50.00% | -0.54 Increased by +133.74% |
| Mar 31, 23 | -0.21 Increased by +30.00% | -0.21 |
| Mar 17, 23 | -2.10 Decreased by -337.50% | -2.10 |
| Nov 17, 22 | -0.30 Decreased by -151.72% | -0.36 Increased by +46.30% |
| Nov 14, 22 | -0.30 Increased by +43.40% | -0.36 Increased by +46.30% |
| Aug 15, 22 | -0.30 Increased by +48.28% | -0.46 Increased by +75.61% |
| May 16, 22 | -0.48 Increased by +69.23% | -0.43 Decreased by -27.04% |
| Mar 30, 22 | 0.58 Increased by +130.53% | -0.62 Increased by +312.17% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 23 | 0.00 Decreased by -100.00% | -4.47 M Increased by +67.53% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by -100.00% | -11.51 M Decreased by -188.25% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by -100.00% | -14.47 M Increased by +7.88% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 653.00 K Increased by +20.93% | -9.48 M Increased by +44.47% | Decreased by -1.45 K% Increased by +54.08% |
| Mar 31, 22 | 1.65 M Increased by +344.20% | -13.76 M Increased by +62.50% | Decreased by -834.89% Increased by +91.56% |
| Dec 31, 21 | 25.94 M Increased by +5.55 K% | 13.04 M Increased by +145.17% | Increased by +50.28% Increased by +100.80% |
| Sep 30, 21 | 1.46 M Increased by +76.54% | -15.70 M Increased by +11.12% | Decreased by -1.08 K% Increased by +49.66% |
| Jun 30, 21 | 540.00 K Decreased by -25.93% | -17.07 M Increased by +16.07% | Decreased by -3.16 K% Decreased by -13.30% |
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primarily in the kidney and lung. It also develops ANG-3777, a hepatocyte growth factor mimetic to treat acute organ injuries, such as delayed graft function; ROCK2 inhibitors programs for fibrotic diseases; and CYP11B2 inhibitor program. The company was incorporated in 1998 and is based in Uniondale, New York.